Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Colorectal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
CA
  • AVASTIN (bevacizumab for injection) is indicated for: • Metastatic Colorectal Cancer (mCRC) - Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum. - Consideration should be given to current standard of care guidelines for colorectal cancer. - See Drug-Drug Interactions for further information on the use of Avastin in combination with irinotecan. - Please refer to the Product Monographs for irinotecan, 5-fluorouracil and leucovorin for additional information on these products, and...
Product first approved 2005Health Canada
EU
  • Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines...
Product first approved 2005EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (300)
Cervical Cancer
NCT05715840 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-01-31 – 2026-05-31 · Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
What this study did
Colorectal Cancer
NCT05797467 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-04-01 – 2033-04-01 · Colorectal Cancer, Chemotherapy Effect
What this study did
NCT06791512 · Jun Huang
2025-01-18 – 2031-12-31 · Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
What this study did
NCT07271355 · City of Hope Medical Center
2027-01-04 – 2031-02-28 · Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
What this study did
NCT07722494 · Innovent Biologics (Suzhou) Co. Ltd.
2026-07-31 – 2030-12-31 · Colorectal Cancer
What this study did
NCT07676162 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-08-28 – 2029-09 · Advanced Colorectal Cancer
What this study did
NCT07729605 · Sun Yat-sen University
2026-07-30 – 2029-07-30 · Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
What this study did
NCT06497985 · Chipscreen Biosciences, Ltd.
2024-12-06 – 2028-09-30 · Colorectal Cancer
What this study did
NCT04687631 · Fudan University
2021-01-14 – 2027-09-30 · Colorectal Cancer, Liver Metastases
What this study did
NCT02997228 · National Cancer Institute (NCI)
2018-01-19 – 2027-06-01 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
What this study did
NCT06566755 · Caigang Liu
2024-02-01 – 2027-02-01 · Colorectal Cancer
What this study did
NCT03303495 · Sun Yat-sen University
2011-11-14 – 2026-12-31 · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
What this study did
NCT02162563 · Dutch Colorectal Cancer Group
2014-07 – 2025-01 · Colorectal Cancer, Liver Metastases
What this study did
NCT04525326 · Fudan University
2020-10-01 – 2022-11-01 · Colorectal Cancer, Liver Metastases
What this study did
NCT01996306 · Epidemiological and Clinical Research Information Network
2013-12-02 – 2018-06-30 · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
What this study did
NCT01918852 · Dutch Colorectal Cancer Group
2013-12 – 2018-03 · Colorectal Cancer, Metastases
What this study did
NCT00433927 · PD Dr. med. Volker Heinemann
2007-01 – 2016-12 · Neoplasm Metastasis, Colorectal Cancer
What this study did
NCT01249638 · Ludwig-Maximilians - University of Munich
2010-12 – 2016-12 · Colorectal Cancer Metastatic
What this study did
NCT00394992 · Dutch Colorectal Cancer Group
2006-12 – 2013-08 · Colorectal Cancer, Liver Metastases
What this study did
NCT01167725 · Alliance for Clinical Trials in Oncology
2010-08 – 2012-01 · Colorectal Cancer
What this study did
NCT00062426 · Prologue Research International
2003-05 – 2011-02 · Colorectal Cancer
What this study did
NCT00469443 · Hellenic Oncology Research Group
2006-12 – 2010-02 · Colorectal Cancer
What this study did
NCT00208546 · Dutch Colorectal Cancer Group
2005-06 – 2009-12 · Colorectal Cancer
What this study did
NCT01169558 · Hoffmann-La Roche
2006-05 – 2009-07 · Colorectal Cancer
What this study did
NCT00115765 · Amgen
2005-06-01 – 2009-05-01 · Colorectal Cancer
What this study did
NCT00101686 · Pfizer
2003-02 – 2008-10 · Colorectal Neoplasms
What this study did
NCT00070122 · National Cancer Institute (NCI)
2004-04 – 2007-01 · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
What this study did
NCT00096967 · Genentech, Inc.
2002-10 – 2004-07 · Breast Cancer, Colorectal Cancer, Metastases
What this study did
Hepatocellular Carcinoma
NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-10-20 – 2032-09 · Hepatocellular Carcinoma
What this study did
NCT07691762 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-11 – 2031-09 · Hepatocellular Carcinoma
What this study did
NCT06618664 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-10-28 – 2030-12 · Advanced Hepatocellular Carcinoma
What this study did
NCT06680258 · Tempest Therapeutics
2025-12 – 2030-07 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07594340 · Binkui Li
2026-05-15 – 2030-05-30 · Hepatocellular Carcinoma
What this study did
NCT06921785 · AstraZeneca
2025-05-06 – 2030-03-15 · Hepatocellular Carcinoma
What this study did
NCT04712643 · Hoffmann-La Roche
2021-03-12 – 2029-02-01 · Hepatocellular Carcinoma
What this study did
NCT05482516 · Georgetown University
2023-03-29 – 2027-12 · Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
What this study did
NCT05985798 · Second Affiliated Hospital of Guangzhou Medical University
2023-08-01 – 2027-07-31 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT04803994 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2021-07-06 – 2027-07 · Hepatocellular Carcinoma
What this study did
NCT03778957 · AstraZeneca
2018-11-30 – 2026-08-31 · Hepatocellular Carcinoma
What this study did
NCT03847428 · AstraZeneca
2019-04-29 – 2026-07-27 · Hepatocellular Carcinoma
What this study did
NCT04723004 · Shanghai Junshi Bioscience Co., Ltd.
2020-10-15 – 2024-05-31 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
Phase 2/3 (66)
Cervical Cancer
NCT06123884 · Bio-Thera Solutions
2023-12-13 – 2027-01 · Cervical Cancer
What this study did
NCT04138992 · Air Force Military Medical University, China
2020-08-01 – 2022-05-31 · Disease Free Survival
What this study did
Colorectal Cancer
NCT06280495 · Sun Yat-sen University
2024-02-01 – 2029-12-31 · Colorectal Cancer, Liver Metastases
What this study did
NCT02758951 · Koen Rovers
2017-06-01 – 2029-06-01 · Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant, Colorectal Carcinoma, Colorectal Adenocarcinoma, Peritoneal Neoplasms, Peritoneal Carcinomatosis, Peritoneal Cancer, Peritoneal Metastases, Peritoneal Neoplasm Malignant Secondary Carcinomatosis, Peritoneal Neoplasm Malignant Secondary
What this study did
NCT03686254 · Nanfang Hospital, Southern Medical University
2018-07-16 – 2023-10-01 · Colorectal Neoplasms Malignant
What this study did
NCT00975897 · Medical Research Council
2009-07 – 2012-12 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT07490262 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2026-03-27 – 2030-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd.
2026-03-01 – 2030-03-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05976568 · Qilu Pharmaceutical Co., Ltd.
2023-09-01 – 2027-09-01 · Hepatocellular Carcinoma
What this study did
NCT07285850 · Eastern Hepatobiliary Surgery Hospital
2025-10-20 – 2026-08-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT05665348 · Federation Francophone de Cancerologie Digestive
2023-03-09 – 2025-05-12 · HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
What this study did
Metastatic Colorectal Cancer
NCT07585279 · Hebei Medical University Fourth Hospital
2026-05-20 – 2032-02-28 · Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
What this study did
NCT06958419 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-05-01 – 2031-12-31 · Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)
What this study did
NCT05462613 · Centre Hospitalier Universitaire de Besancon
2023-05-09 – 2030-11 · Metastatic Colorectal Cancer
What this study did
NCT05141721 · Seattle Project Corporation
2022-02-12 – 2027-03 · Colorectal Neoplasms
What this study did
NCT00952029 · Federation Francophone de Cancerologie Digestive
2010-03 – 2018-01 · Colorectal Cancer
What this study did
NCT00294359 · Australasian Gastro-Intestinal Trials Group
2005-06 – 2007-07 · Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT05807893 · Sun Yat-sen University
2023-05-14 – 2024-05-15 · Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases
What this study did
Ovarian Cancer
NCT07472140 · N.N. Alexandrov National Cancer Centre
2025-07-01 – 2033-06-30 · Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
What this study did
NCT02641639 · Mateon Therapeutics
2016-06 – 2017-10 · Platinum Resistant Ovarian Cancer
What this study did
Other / comorbidity
NCT06264531 · Fondation Ophtalmologique Adolphe de Rothschild
2026-01-16 – 2029-01-15 · Cerebral AV Malformation
What this study did
NCT05063552 · National Cancer Institute (NCI)
2023-03-13 – 2027-12-15 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
What this study did
NCT07134218 · Changhai Hospital
2025-10 – 2027-10 · Rectal Cancer
What this study did
NCT02839707 · National Cancer Institute (NCI)
2017-06-23 – 2027-05-11 · Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
What this study did
NCT06595355 · Isfahan University of Medical Sciences
2021-10-10 – 2025-09-22 · Diabetic Macular Edema, Macular Edema, Retinal Neovascularization
What this study did
NCT00346814 · Asociación para Evitar la Ceguera en México
2007-07 – 2024-11 · Retinopathy of Prematurity
What this study did
NCT01236560 · National Cancer Institute (NCI)
2011-01-26 – 2023-12-31 · Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Spinal Cord Neoplasm
What this study did
NCT05582577 · Shahid Beheshti University of Medical Sciences
2022-10-15 – 2023-12-15 · Diabetic Macular Edema
What this study did
NCT05083689 · Shahid Beheshti University of Medical Sciences
2021-10-06 – 2022-04 · Diabetic Macular Edema
What this study did
NCT04511715 · Shahid Beheshti University of Medical Sciences
2020-09-01 – 2021-11-01 · Non-proliferative Diabetic Retinopathy
What this study did
NCT04119921 · Shahid Beheshti University of Medical Sciences
2018-01-01 – 2020-06-20 · DME
What this study did
NCT03821168 · Shahid Beheshti University of Medical Sciences
2019-03-01 – 2019-10-01 · Refractory Diabetic Macular Edema
What this study did
NCT03609307 · Shahid Beheshti University of Medical Sciences
2018-09 – 2019-02 · Age Related Macular Degeneration
What this study did
NCT03391219 · Shahid Beheshti University of Medical Sciences
2018-01 – 2018-10 · Retinal Vein Occlusion
What this study did
NCT02985619 · University of Sao Paulo
2016-07-21 – 2017-12-21 · Diabetic Macular Edema
What this study did
NCT00450203 · Professor David Cunningham
2007-10 – 2017-12 · Oesophagogastric Cancer
What this study did
NCT02705274 · Marashi Eye Clinic
2016-02 – 2017-05 · Proliferative Diabetic Retinopathy
What this study did
NCT00651456 · Intergroupe Francophone de Cancerologie Thoracique
2008-02 – 2016-09 · Mesothelioma
What this study did
NCT02296567 · East Florida Eye Institute
2014-12 – 2016-07 · Age Related Macular Degeneration
What this study did
NCT01635790 · Prof. dr. R.O. Schlingemann
2012-06 – 2016-06 · Diabetic Macular Edema
What this study did
NCT01635803 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2012-06 – 2016-06 · Retinal Vein Occlusion
What this study did
NCT00227617 · University of California, San Francisco
2005-06-08 – 2016-02 · Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
What this study did
NCT02645734 · Shahid Beheshti University of Medical Sciences
est. completion 2016-02 · Diabetic Macular Edema
What this study did
NCT02901236 · Athens Vision Eye Institute
2014-01 – 2016-01 · Glaucoma
What this study did
Phase 2 (1366)
Cervical Cancer
NCT07497074 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2026-04 – 2028-06 · Cervical Cancer
What this study did
NCT07054567 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-08-21 – 2027-12 · Cervical Cancer, Endometrial Cancer
What this study did
NCT05444374 · Sichuan Cancer Hospital and Research Institute
2022-10-01 – 2025-12-31 · Cervical Cancer
What this study did
NCT05998941 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-08 – 2025-06 · Cervical Cancer
What this study did
NCT04868708 · Akeso
2021-04-01 – 2024-02-28 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT04973904 · Peking Union Medical College Hospital
2021-08-01 – 2023-12-01 · Cervical Cancer
What this study did
NCT03476798 · University of Oklahoma
2018-06-29 – 2023-09-29 · Cervical Cancer, Endometrial Cancer
What this study did
NCT03367871 · University of Miami
2018-09-06 – 2023-01-30 · Cervical Cancer
What this study did
NCT02921269 · National Cancer Institute (NCI)
2017-03-10 – 2021-01-13 · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
What this study did
NCT03912402 · Biocad
2018-12-25 – 2020-07-07 · Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent
What this study did
NCT02467907 · Hoffmann-La Roche
2015-07-28 – 2019-01-15 · Cervical Cancer
What this study did
NCT00369122 · National Cancer Institute (NCI)
2006-08-11 – 2016-12-15 · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
What this study did
NCT00545792 · Dana-Farber Cancer Institute
2007-05 – 2013-10 · Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer, Carcinoma of the Vulva
What this study did
NCT00548418 · Washington University School of Medicine
2007-02 – 2012-12 · Cervical Cancer
What this study did
NCT00626561 · M.D. Anderson Cancer Center
2008-02 – 2011-07 · Cervical Cancer, Uterine Cancer
What this study did
NCT00600210 · Leo W. Jenkins Cancer Center
2008-01 – 2011-04 · Cervical Cancer
What this study did
NCT00025233 · National Cancer Institute (NCI)
2002-04 – 2009-07 · Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
What this study did
Colorectal Cancer
NCT02487992 · The First People's Hospital of Changzhou
2015-07 – 2045-07 · Colorectal Neoplasms
What this study did
NCT07728019 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-07-30 – 2031-12-31 · CRC (Colorectal Cancer)
What this study did
NCT07071714 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-07-22 – 2031-10 · Colorectal Cancer
What this study did
NCT07926477 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-12-01 – 2030-12-01 · Colorectal Cancer
What this study did
NCT07819604 · Xijing Hospital
2026-09-01 – 2030-09-01 · Locally Advanced Colorectal Cancer
What this study did
NCT07134101 · The First Affiliated Hospital with Nanjing Medical University
2025-09-01 – 2030-08-31 · Colorectal Cancer (Diagnosis)
What this study did
NCT07011550 · M.D. Anderson Cancer Center
2025-08-15 – 2030-07-01 · Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
What this study did
NCT07797244 · Dai, Guanghai
2026-10-29 – 2029-10 · Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
What this study did
NCT07527858 · Gilead Sciences
2026-05-19 – 2028-12 · Advanced Microsatellite Stable Colorectal Cancer
What this study did
NCT05999812 · University of Texas Southwestern Medical Center
2023-12-19 – 2028-10-01 · Colorectal Cancer
What this study did
NCT07123441 · Sanjun Cai
2025-09-01 – 2028-09-01 · Colorectal Cancer
What this study did
NCT07106034 · Shanghai Pudong Hospital
2025-08-31 – 2028-07-31 · Advanced Colorectal Cancer
What this study did
NCT06268015 · Nicholas DeVito, MD
2024-11-18 – 2028-07 · Colorectal Cancer
What this study did
NCT06881537 · Shanghai Changzheng Hospital
2024-06-01 – 2028-06-30 · Locally Recurrent Colorectal Cancer
What this study did
NCT07474727 · Multitude Therapeutics Inc.
2026-04-29 – 2028-02-28 · Colorectal Cancer
What this study did
NCT07562490 · Fudan University
2025-04-01 – 2027-12-31 · ctDNA, Chemotherapy, Colorectal Cancer
What this study did
NCT07007767 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-15 – 2027-12-30 · Colorectal Cancer Metastatic
What this study did
NCT06973343 · Anhui Provincial Cancer Hospital
2025-05 – 2027-12 · Colorectal Cancer Metastatic
What this study did
NCT06540326 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-11-12 – 2027-10-31 · Colorectal Cancer Metastatic
What this study did
NCT06092242 · The Second Affiliated Hospital of Shandong First Medical University
2023-10-15 – 2027-10-15 · Colorectal Cancer
What this study did
NCT05489211 · AstraZeneca
2022-09-06 – 2027-10-01 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
What this study did
NCT06788171 · Fujian Cancer Hospital
2026-05-09 – 2027-09-01 · Colorectal Cancer Liver Metastasis
What this study did
NCT07047560 · Tianjin Medical University Cancer Institute and Hospital
2024-09-01 – 2027-08-01 · Colorectal Cancer (CRC)
What this study did
NCT05364489 · The First Affiliated Hospital of Zhengzhou University
2022-06-15 – 2027-06-15 · Advanced Colorectal Cancer
What this study did
NCT05969899 · Fudan University
2023-07-10 – 2027-02-10 · Colorectal Cancer
What this study did
NCT06801665 · Hua Jiang
2025-04-17 – 2027-02-01 · Colorectal Cancer Liver Metastasis
What this study did
NCT05727163 · Sun Yat-sen University
2022-07-29 – 2026-12-31 · Colorectal Cancer Metastatic
What this study did
NCT06643793 · Affiliated Hospital of Nantong University
2024-11-04 – 2026-12-31 · Colorectal Neoplasms Malignant
What this study did
NCT06764680 · Sun Yat-sen University
2024-12-31 – 2026-12-31 · Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy, Radiotherapy, Intensity-Modulated
What this study did
NCT07007728 · Peking University Cancer Hospital & Institute
2025-06-01 – 2026-12-31 · Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
What this study did
Phase 1/2 (245)
Cervical Cancer
NCT06543576 · Jonsson Comprehensive Cancer Center
2025-07-29 – 2032-01-31 · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
What this study did
NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09-23 – 2027-12 · Cervical Cancer
What this study did
NCT06859775 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2027-01 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT03786081 · Seagen, a wholly owned subsidiary of Pfizer
2019-02-27 – 2026-03-19 · Cervical Cancer
What this study did
Colorectal Cancer
NCT07805551 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2026-08-18 – 2032-08 · CRC, Colorectal Cancer
What this study did
NCT06445062 · Revolution Medicines, Inc.
2024-05-24 – 2030-03-30 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07283367 · Hansoh BioMedical R&D Company
2025-12-22 – 2029-12-31 · CRC
What this study did
NCT07737600 · Lepu Biopharma Co., Ltd.
2026-08 – 2029-12 · Advanced Colorectal Cancer
What this study did
NCT07863869 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-09 – 2029-11-27 · Colorectal Cancer Metastatic to Liver
What this study did
NCT07900165 · CytomX Therapeutics
2026-12 – 2029-02 · Colo-rectal Cancer
What this study did
NCT05482893 · Phanes Therapeutics
2023-03-15 – 2028-04 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
What this study did
NCT05919264 · Parabilis Medicines, Inc.
2023-05-23 – 2027-08-31 · Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
What this study did
NCT07044908 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2025-07-30 – 2027-07 · RAS/BRAF Wild Type Colorectal Cancer
What this study did
NCT07491159 · Tianjin Medical University Cancer Institute and Hospital
2023-07-01 – 2026-12-30 · Colorectal Cancer
What this study did
NCT04068610 · MedImmune LLC
2019-09-13 – 2026-11-24 · Metastatic Microsatellite-stable Colorectal Cancer
What this study did
NCT06373133 · West China Hospital
2024-05-01 – 2026-11-01 · Colorectal Cancer
What this study did
NCT04940546 · Sun Yat-sen University
2021-06-16 – 2025-10-30 · Colorectal Cancer Metastatic
What this study did
NCT03795311 · Centre Georges Francois Leclerc
2018-11-07 – 2025-07-16 · Colorectal Cancer
What this study did
NCT03428958 · NuCana plc
2018-10-05 – 2024-03-21 · Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
What this study did
NCT02826837 · Taiwan Leader Biotech Corp.
2022-09-01 – 2024-02-01 · Advanced Colorectal Cancer
What this study did
NCT04988191 · Peking University
2020-12-24 – 2023-12-24 · Colorectal Carcinoma
What this study did
NCT03169777 · ImmunityBio, Inc.
2018-08 – 2021-12-28 · Colorectal Cancer
What this study did
NCT02244632 · Isofol Medical AB
2014-09 – 2020-01-30 · Colorectal Neoplasm
What this study did
NCT01206530 · Abramson Cancer Center at Penn Medicine
2010-09 – 2017-09 · Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
What this study did
NCT01047293 · University of Utah
2010-05 – 2015-08 · Colorectal Cancer
What this study did
NCT00784446 · University of Cologne
2008-04 – 2012-12 · Stage IV Colorectal Cancer
What this study did
NCT00345761 · Chugai Pharmaceutical
2006-02 – 2010-07 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05468359 · St. Jude Children's Research Hospital
2022-11-07 – 2037-06 · Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer, Pediatric Solid Tumor, Fibrolamellar Carcinoma
What this study did
NCT06725121 · University Health Network, Toronto
2024-12 – 2034-06 · Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
What this study did
NCT07761286 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-09-30 – 2031-09-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT03942328 · Mayo Clinic
2019-09-19 – 2030-08-31 · Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT07714317 · Shanghai Zhongshan Hospital
2026-07-20 – 2030-05-31 · Resectable Hepatocellular Carcinoma
What this study did
NCT07835737 · West China Hospital
2026-10-01 – 2029-10-01 · Unresectable Hepatocellular Carcinoma
What this study did
NCT07479485 · Lepu Biopharma Co., Ltd.
2026-04-08 – 2029-04 · Hepatocellular Carcinoma
What this study did
NCT05109052 · University of Rochester
2022-09-20 – 2028-12-31 · Hepatocellular Carcinoma, Cancer of Liver
What this study did
NCT06294548 · University of Alabama at Birmingham
2025-07-29 – 2028-08-28 · Hepatocellular Carcinoma
What this study did
NCT06995105 · Zhejiang University
2025-04-09 – 2028-04-01 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT07522411 · BinYong Liang
2026-04-30 – 2028-02 · Hepatocellular Carcinoma
What this study did
NCT05440708 · Tvardi Therapeutics, Incorporated
2023-03-23 – 2027-07-20 · Hepatocellular Carcinoma
What this study did
NCT05824975 · GI Innovation, Inc.
2023-05-30 – 2027-04-24 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
What this study did
NCT05444088 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-08-02 – 2026-06-30 · Advanced Hepatocellular Carcinoma
What this study did
NCT05337137 · Bristol-Myers Squibb
2022-05-05 – 2025-11-18 · Carcinoma, Hepatocellular
What this study did
NCT05908786 · Hoffmann-La Roche
2023-12-05 – 2025-11-13 · Carcinoma, Hepatocellular
What this study did
NCT05603039 · Qilu Pharmaceutical Co., Ltd.
2021-07-01 – 2023-12-30 · Advanced Liver Cancer
What this study did
NCT06006286 · M.D. Anderson Cancer Center
2023-08-08 – 2023-11-10 · Metastatic Hepatocellular Carcinoma
What this study did
NCT04843943 · Fudan University
2021-05-01 – 2023-05-01 · Hepatocellular Carcinoma
What this study did
Metastatic Colorectal Cancer
NCT07750041 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-08-30 – 2029-08-30 · Unresectable Advanced or Metastatic Colorectal Cancer
What this study did
NCT07391566 · Luye Pharma Group Ltd.
2026-03-31 – 2028-12-31 · Metastatic Colorectal Cancer (mCRC)
What this study did
NCT07653685 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2026-09-03 – 2028-12 · Colorectal Cancer
What this study did
Phase 1 (370)
Cervical Cancer
NCT04551950 · EMD Serono Research & Development Institute, Inc.
2020-10-19 – 2022-06-30 · Cervical Cancer
What this study did
NCT05476341 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2017-04-06 – 2017-08-18 · Rectal Cancer, Lung Cancer, Ovarian Cancer, Cervical Cancer, Glioblastoma
What this study did
Colorectal Cancer
NCT07066657 · ArriVent BioPharma, Inc.
2025-07-25 – 2030-12 · Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
What this study did
NCT07318805 · Pfizer
2025-12-23 – 2030-04-14 · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
What this study did
NCT05647122 · AstraZeneca
2022-12-21 – 2028-08-03 · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
What this study did
NCT06663319 · Janssen Research & Development, LLC
2024-10-15 – 2028-07-19 · Colorectal Neoplasms, Gastrointestinal Neoplasms
What this study did
NCT07193862 · Northwell Health
2025-12-10 – 2028-04-15 · Colorectal Cancer Metastatic
What this study did
NCT06540261 · Ono Pharmaceutical Co., Ltd.
2021-09-23 – 2027-12-31 · Unresectable Colorectal Cancer
What this study did
NCT06307249 · Lebanese University
2023-02-15 – 2027-12 · Cancer, Solid Tumor, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Targeted Therapy, Chemotherapy, Immunotherapy, Precision Therapy
What this study did
NCT06547385 · Ono Pharmaceutical Co., Ltd.
2021-01-13 – 2027-10-31 · Colorectal Cancer
What this study did
NCT01061515 · Washington University School of Medicine
2011-05-10 – 2027-09-27 · Carcinoma
What this study did
NCT06004245 · Vividion Therapeutics, Inc.
2024-01-25 – 2027-05-31 · Advanced Solid Tumors, Colorectal Cancer
What this study did
NCT05464030 · EMD Serono Research & Development Institute, Inc.
2022-08-04 – 2026-10-23 · Colorectal Cancer
What this study did
NCT06838338 · Jian Li
2025-03-20 – 2026-08 · Colorectal Cancer
What this study did
NCT06717880 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-07-28 – 2026-07-31 · Advanced Malignancies
What this study did
NCT06509906 · EMD Serono Research & Development Institute, Inc.
2024-10-08 – 2025-12-02 · Advanced Solid Tumor
What this study did
NCT03597581 · Inspirna, Inc.
2018-06-05 – 2025-03-31 · Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
What this study did
NCT00873275 · City of Hope Medical Center
2009-03-11 – 2025-02-26 · Colorectal Cancer
What this study did
NCT04553692 · IGM Biosciences, Inc.
2020-09-23 – 2025-01-20 · Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
What this study did
NCT04164069 · Anne Noonan
2020-09-02 – 2023-06-22 · Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
What this study did
NCT02876224 · Hoffmann-La Roche
2016-09-30 – 2019-06-25 · Colorectal Cancer
What this study did
NCT02574663 · TG Therapeutics, Inc.
2015-09-11 – 2018-08 · Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)
What this study did
NCT00296062 · Case Comprehensive Cancer Center
2006-03 – 2011-05 · Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01271166 · Novartis Pharmaceuticals
2007-10 – 2009-08 · Advanced Colorectal Cancer
What this study did
NCT00060411 · National Cancer Institute (NCI)
2003-06 – 2007-07 · Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
NCT00047762 · Genentech, Inc.
started 2002-10 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05096715 · Massachusetts General Hospital
2022-08-23 – 2032-01-31 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05363722 · Shanghai Zhongshan Hospital
2025-03-06 – 2029-12 · Hepatocellular Carcinoma
What this study did
NCT05546879 · University Hospital, Grenoble
2023-03-15 – 2029-03-19 · Hepatocellular Carcinoma
What this study did
NCT07557251 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-08-12 – 2028-12 · Advanced HBV-Related Hepatocellular Carcinoma
What this study did
NCT06478693 · Myeloid Therapeutics
2024-07-01 – 2028-05-31 · Hepatocellular Carcinoma
What this study did
NCT07478302 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-04-14 – 2027-12 · Advanced Unresectable Hepatocellular Carcinoma
What this study did
NCT06084481 · AbbVie
2023-11-09 – 2027-09 · Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
What this study did
NCT05097911 · National University Hospital, Singapore
2021-08-02 – 2027-04 · Advanced Hepatocellular Carcinoma
What this study did
NCT04857684 · Massachusetts General Hospital
2021-06-18 – 2026-12-31 · Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
What this study did
NCT05488522 · Abramson Cancer Center at Penn Medicine
2022-09-01 – 2026-12-31 · Hepatocellular Carcinoma
What this study did
NCT05075993 · M.D. Anderson Cancer Center
2021-11-12 – 2026-11-03 · Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
What this study did
NCT05022927 · Chugai Pharmaceutical
2021-06-01 – 2025-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT04592029 · Second Affiliated Hospital of Guangzhou Medical University
2020-10-21 – 2024-03-17 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05093608 · H. Lee Moffitt Cancer Center and Research Institute
2021-11-03 – 2022-10-12 · Hepatocellular Carcinoma
What this study did
NCT03382886 · University of Utah
2018-04-11 – 2019-07-02 · Hepatocellular Carcinoma
What this study did
NCT01441388 · Pfizer
2011-12 – 2013-11 · Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
What this study did
NCT00426829 · M.D. Anderson Cancer Center
2007-05 – 2009-11 · Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
What this study did
Metastatic Colorectal Cancer
NCT07500298 · M.D. Anderson Cancer Center
2026-05-20 – 2032-12-27 · Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
What this study did
NCT04929223 · Hoffmann-La Roche
2021-10-22 – 2030-08-31 · Metastatic Colorectal Cancer
What this study did
NCT07318389 · M.D. Anderson Cancer Center
2026-04-22 – 2029-11-14 · Dynamic Tumor Resistance, Metastatic Colorectal Cancer
What this study did
NCT06011772 · Roswell Park Cancer Institute
2023-12-18 – 2029-02-05 · Colo-rectal Cancer
What this study did
NCT06625775 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
2024-10-29 – 2028-11 · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
What this study did
NCT07656038 · STCube, Inc.
2026-06-30 – 2028-07-31 · Colonrectal Cancer (CRC)
What this study did
NCT06867822 · University of Alabama at Birmingham
2025-07-17 – 2028-07 · Advanced Colorectal Cancer, Metastatic Colorectal Cancer
What this study did
Phase 4 (73)
Cervical Cancer
NCT07645625 · University Medical Center Groningen
2026-05-11 – 2039-02 · Cervical Cancer
What this study did
Colorectal Cancer
NCT06269445 · Sir Run Run Shaw Hospital
2024-01-01 – 2026-02-01 · Colorectal Cancer
What this study did
NCT04813913 · University Hospital, Rouen
2019-05-05 – 2022-07-21 · Oncology
What this study did
NCT01972490 · Xu jianmin
2013-10 – 2019-06 · Colorectal Neoplasms
What this study did
NCT00577031 · Hoffmann-La Roche
2008-02 – 2011-08 · Colorectal Cancer
What this study did
NCT00327093 · Hospices Civils de Lyon
2006-05 – 2008-10 · Colorectal Cancer, Neoplasm Metastasis
What this study did
NCT02582970 · Hoffmann-La Roche
2005-05 – 2008-04 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05185505 · The Methodist Hospital Research Institute
2023-01-30 – 2028-10-31 · Hepatocellular Carcinoma, Hepatocellular Cancer
What this study did
NCT07059494 · Icahn School of Medicine at Mount Sinai
2026-03-26 – 2028-08-01 · Hepatocellular Carcinoma
What this study did
NCT06590844 · Anhui Provincial Hospital
2023-12-19 – 2026-03 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05717400 · M.D. Anderson Cancer Center
2023-03-17 – 2024-08-29 · Liver Cancer
What this study did
Metastatic Colorectal Cancer
NCT06843954 · Mohammed Mahmood Mohammed
2022-09-01 – 2023-11-30 · Colo-rectal Cancer
What this study did
NCT01588990 · Hoffmann-La Roche
2012-06-26 – 2016-09-30 · Colorectal Neoplasms
What this study did
NCT00114946 · Genentech, Inc.
2005-05 – 2007-12 · Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT02316327 · Fundacion Clinic per a la Recerca Biomédica
2013-07 – 2016-10 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT00451906 · Hoffmann-La Roche
2006-08 – 2009-06 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT01932125 · Hoffmann-La Roche
2018-12-05 – 2025-06-18 · Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
What this study did
NCT01706120 · National Cancer Institute, Naples
2012-10 – 2024-12 · Ovarian Cancer
What this study did
Other / comorbidity
NCT07004335 · Hebei Medical University Fourth Hospital
2025-07-01 – 2029-01-31 · PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, Bevacizumab
What this study did
NCT05525767 · Hebei Medical University Fourth Hospital
2022-03-31 – 2028-12-31 · Solid Tumor
What this study did
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT06121401 · Mario Negri Institute for Pharmacological Research
2023-09-15 – 2027-09-15 · Carcinoma, Ovarian Epithelial
What this study did
NCT07014280 · Kasr El Aini Hospital
2023-09-01 – 2025-07-01 · Keloids
What this study did
NCT03211741 · University Hospital, Ghent
2013-11-22 – 2024-07-09 · Retinal Neovascularization, Macular Edema
What this study did
NCT04674254 · Cairo University
2021-03-30 – 2023-03-15 · Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
What this study did
NCT04991350 · Cairo University
2021-11-26 – 2022-11-01 · Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
What this study did
NCT05314673 · University Hospital Fattouma Bourguiba
2019-01-01 – 2021-01-01 · Pterygium
What this study did
NCT03892434 · Yeungnam University College of Medicine
2019-03-18 – 2020-06-18 · Branch Retinal Vein Occlusion With Macular Edema
What this study did
NCT03037736 · University of California, San Francisco
2020-03-01 – 2020-03-01 · Pterygium of Conjunctiva and Cornea
What this study did
NCT02389959 · Stanford University
2014-08-04 – 2020-01-23 · HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
What this study did
NCT03246152 · Cairo University
2017-10-23 – 2018-12-24 · Diabetic Macular Edema, Ischemic Maculopathy
What this study did
NCT03340610 · Southeast Retina Center, Georgia
2015-06 – 2018-12-12 · Diabetic Macular Edema
What this study did
NCT02530801 · University of Nottingham
2017-01 – 2018-08 · Recurrent Pterygium
What this study did
NCT02594423 · University of Nottingham
2015-12 – 2018-08 · Corneal Neovascularisation
What this study did
NCT02248571 · iOMEDICO AG
2014-08 – 2017-09-30 · Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT03552770 · University Hospital of Ferrara
2014-11-23 – 2016-12-29 · Age-Related Macular Degeneration
What this study did
NCT01229202 · Nova Scotia Health Authority
2008-07 – 2016-01 · Glaucoma
What this study did
NCT01094184 · Hoffmann-La Roche
2010-03 – 2015-12 · Breast Cancer
What this study did
NCT02036424 · Raj K. Maturi, MD
2014-01 – 2015-08 · Diabetic Macular Edema
What this study did
NCT02096874 · King Khaled Eye Specialist Hospital
2013-06 – 2015-06 · Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
What this study did
NCT01962376 · Hebei Medical University
2013-02 – 2015-04 · Gastric Cancer, Liver Metastasis
What this study did
NCT01127360 · Oslo University Hospital
2009-03 – 2014-08 · Exudative Age-related Macular Degeneration
What this study did
NCT00682539 · Medical University of Vienna
2007-10 – 2014-07 · Diabetic Macular Edema
What this study did
NCT01854593 · Nihon University
2012-05 – 2014-03 · Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment, Vitreous Hemorrhage
What this study did
Early phase / not applicable (142)
Cervical Cancer
NCT06878196 · Obstetrics & Gynecology Hospital of Fudan University
2025-03-10 – 2028-12 · Uterine Cervical Neoplasm
What this study did
Colorectal Cancer
NCT06177288 · Fudan University
2024-01-01 – 2025-05-01 · Colorectal Neoplasms
What this study did
NCT05497726 · Meander Medical Center
2023-01-27 – 2023-10-10 · Colorectal Neoplasms, Colon Neoplasm, Sentinel Lymph Node, Fluorescence
What this study did
NCT05498051 · Meander Medical Center
2022-09-01 – 2023-06-01 · Colonic Neoplasms, Sentinel Lymph Node, Fluorescence, Colorectal Neoplasms
What this study did
NCT01834014 · EPS Corporation
2013-05 – 2017-03 · Liver Metastasis, Colorectal Cancer
What this study did
NCT01405430 · Centre Leon Berard
2010-05 – 2014-05 · Colorectal Cancer, Metastasis
What this study did
NCT00462501 · Memorial Sloan Kettering Cancer Center
2007-03 – 2014-02 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT07281664 · Third Affiliated Hospital, Sun Yat-Sen University
2026-01-01 – 2029-12-31 · Hepatocellular Carcinoma, Transarterial Chemoembolization
What this study did
NCT07543510 · Third Affiliated Hospital, Sun Yat-Sen University
2026-05-01 – 2029-08-31 · Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
What this study did
NCT06893887 · Nanjing Tianyinshan Hospital
2025-05-22 – 2028-12-15 · Hepatocellular Carcinoma(HCC)
What this study did
NCT06595108 · Yonsei University
2024-05-28 – 2028-03-27 · Advanced Hepatocellular Carcinoma, Chemotherapy, Stereotactic Body Radiotherapy
What this study did
NCT04180072 · National Health Research Institutes, Taiwan
2020-03-12 – 2026-12-31 · Carcinoma, Hepatocellular
What this study did
NCT06961526 · Tanta University
2025-02-15 – 2026-07 · Esophageal and/or Gastric Varices, Hepatocellular Carcinoma (HCC)
What this study did
NCT06609863 · Sun Yat-sen University
2024-10-01 – 2026-06-30 · Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
What this study did
NCT06233994 · Changsha Taihe Hospital
2024-01 – 2026-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT05705791 · Gustave Roussy, Cancer Campus, Grand Paris
2023-02-07 – 2025-12-24 · Hepatocellular Carcinoma
What this study did
NCT07272265 · Sun Yat-sen University
2020-10-28 – 2025-11-10 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07075562 · The First Hospital of Hebei Medical University
2021-06-01 – 2025-05-30 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05530785 · Yongchang Zhang
2022-08-01 – 2024-10-01 · Hepatocellular Carcinoma Non-resectable
What this study did
NCT05277675 · Southwest Hospital, China
2021-11-01 – 2023-10-30 · Hepatocellular Carcinoma Recurrent
What this study did
Metastatic Colorectal Cancer
NCT01792934 · Radboud University Medical Center
2013-05 – 2028-05 · Multi-organ Metastatic Colorectal Cancer
What this study did
NCT05991102 · Charite University, Berlin, Germany
2023-12-15 – 2026-11 · Refractory Metastatic Colorectal Cancer
What this study did
NCT02256800 · Jaw-Yuan Wang, MD, PhD
2014-08-13 – 2017-11-30 · Metastatic Colorectal Cancer
What this study did
NCT01810744 · Centre Georges Francois Leclerc
2013-05 – 2015-05 · Metastatic Colorectal Cancer, Glioblastoma, Bevacizumab, Capillaroscopy
What this study did
NCT01280643 · Fox Chase Cancer Center
2010-03 – 2014-05 · Metastatic Colorectal Cancer
What this study did
NCT00489697 · University Hospital, Tours
2007-01 – 2012-11 · Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07870733 · Shanghai Pulmonary Hospital, Shanghai, China
2026-09-15 – 2031-07-01 · ALK, NSCLC, Neoadjuvant Therapy
What this study did
NCT07398599 · Second Affiliated Hospital of Nanchang University
2026-02-15 – 2027-12-30 · Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer
What this study did
NCT05407155 · Fudan University
2022-06-09 – 2026-08-30 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT04973293 · Ruijin Hospital
2022-10-01 – 2025-12-31 · Lung Neoplasm Malignant
What this study did
NCT06643000 · Henan Cancer Hospital
2024-12-20 – 2025-05-30 · Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
What this study did
NCT04944069 · Second Affiliated Hospital of Nanchang University
2021-07 – 2025-03 · NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation
What this study did
NCT02195336 · Karl Kölbeck
2014-08 – 2018-06 · Non-small Cell Lung Cancer
What this study did
NCT01063283 · University of Chicago
2010-03 – 2016-06 · Advanced Non-squamous Non-Small Cell Lung Cancer
What this study did
NCT01006226 · Washington University School of Medicine
— · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00675597 · Memorial Sloan Kettering Cancer Center
2008-05 – 2012-02 · Lung Cancer
What this study did
Ovarian Cancer
NCT06292286 · The University of Hong Kong
2023-11-01 – 2026-12-31 · Recurrent Ovarian Carcinoma
What this study did
NCT01223235 · Memorial Sloan Kettering Cancer Center
2010-10 – 2017-09 · Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
What this study did
Recurrent Glioblastoma
NCT07274787 · University of Cincinnati
2026-12-01 – 2029-12-01 · GBM
What this study did
NCT05284643 · University of Miami
2022-09-30 – 2029-09-30 · Recurrent Glioblastoma
What this study did
NCT07074756 · Mayo Clinic
2025-09-12 – 2028-08-31 · Glioma, Recurrent Glioma, Recurrent Glioblastoma
What this study did
NCT03115333 · ECOG-ACRIN Cancer Research Group
2017-07-25 – 2027-05-07 · Gliosarcoma, Recurrent Glioblastoma
What this study did
NCT05410301 · Varun Monga, MD
2023-04 – 2026-08 · Glioblastoma, Recurrent Glioblastoma
What this study did
NCT05811793 · Second Affiliated Hospital of Nanchang University
2023-04-15 – 2025-12-30 · Glioblastoma
What this study did
NCT01925573 · University of Maryland, Baltimore
2014-05 – 2019-08 · RECURRENT GLIOBLASTOMA, Brain Tumor
What this study did
NCT01987830 · Massachusetts General Hospital
2013-11 – 2019-04 · Recurrent Glioblastoma
What this study did
NCT02076152 · Massachusetts General Hospital
2014-02 – 2019-04 · Recurrent Glioblastoma
What this study did
Used as active comparator (133)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (50)
Cervical Cancer
NCT05798819 · Guangzhou Gloria Biosciences Co., Ltd.
2023-04-20 – 2030-12-01 · Persistent, Recurrent, or Metastatic Cervical Cancer
What this study did
Colorectal Cancer
NCT06997497 · Merck Sharp & Dohme LLC
2025-07-16 – 2030-10-27 · Colon Adenocarcinoma, Rectal Adenocarcinoma
What this study did
NCT05863195 · ECOG-ACRIN Cancer Research Group
2024-04-10 – 2029-06-30 · Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
What this study did
NCT06750094 · Janssen Research & Development, LLC
2024-12-12 – 2029-04-13 · Colorectal Neoplasms
What this study did
NCT03925662 · Sherief Abd-Elsalam
2019-04-01 – 2028-12 · Colorectal Cancer
What this study did
NCT05239741 · Merck Sharp & Dohme LLC
2022-04-02 – 2028-09-19 · Colorectal Neoplasms
What this study did
NCT05540951 · Fudan University
2018-06-01 – 2022-12-30 · Colorectal Cancer
What this study did
NCT02394795 · Takeda
2015-05-29 – 2022-01-14 · Colorectal Cancer
What this study did
NCT00442637 · Dutch Colorectal Cancer Group
2007-01 – 2013-12 · Colorectal Cancer Metastatic
What this study did
Hepatocellular Carcinoma
NCT07823348 · Shanghai Junshi Bioscience Co., Ltd.
2026-10-08 – 2031-10-30 · Hepatocellular Carcinoma
What this study did
Metastatic Colorectal Cancer
NCT07222800 · Pfizer
2025-12-11 – 2031-08-17 · Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
What this study did
NCT07389265 · University of Campania Luigi Vanvitelli
2025-10-01 – 2030-10 · Metastatic Colorectal Cancer (mCRC)
What this study did
NCT05253651 · Seagen, a wholly owned subsidiary of Pfizer
2022-10-24 – 2030-07-03 · Colorectal Neoplasms
What this study did
NCT07362836 · Fudan University
2026-01-31 – 2030-01-30 · Colorectal Cancer
What this study did
NCT07228832 · Summit Therapeutics
2025-11-18 – 2029-11-30 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT06951503 · Akeso
2025-05-27 – 2029-01-07 · Colorectal Adenocarcinoma
What this study did
NCT06992648 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-04-01 – 2027-12-31 · Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
What this study did
NCT04607421 · Pfizer
2020-12-21 – 2027-07-29 · Neoplasms
What this study did
NCT06008119 · Shanghai Kechow Pharma, Inc.
2023-10-25 – 2026-12-24 · Colorectal Cancer Metastatic
What this study did
NCT04854668 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021-05-27 – 2026-12 · Metastatic Colorectal Cancer
What this study did
NCT03511963 · Shanghai Henlius Biotech
2018-04-09 – 2023-04-20 · Metastatic Colorectal Cancer (mCRC)
What this study did
Non-Small Cell Lung Cancer
NCT05318443 · Shanghai Institute Of Biological Products
2020-04-17 – 2023-01-12 · Non-squamous Non-small-cell Lung Cancer
What this study did
NCT04466917 · Amgen
2021-05-15 – 2022-11-13 · Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC
What this study did
NCT03792074 · Sinocelltech Ltd.
2019-02 – 2022-01 · Non-squamous Cell Non-small Cell Lung Cancer
What this study did
NCT04416035 · Zhejiang Teruisi Pharmaceutical Inc.
2020-08-17 – 2021-11-10 · Advanced Non-squamous Non-small-cell Lung Cancer
What this study did
NCT03196986 · Beijing Mabworks Biotech Co., Ltd.
2017-08-15 – 2021-07-30 · Non-small Cell Lung Cancer
What this study did
NCT05169801 · Jiangsu HengRui Medicine Co., Ltd.
2018-01-25 – 2021-06-17 · Non-small Cell Lung Cancer(NSCLC)
What this study did
NCT03329911 · Bio-Thera Solutions
2017-10-20 – 2021-05-27 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT04325698 · Pfizer
2020-06-11 – 2021-05-10 · Advanced Non-squamous NSCLC
What this study did
NCT00948675 · Eli Lilly and Company
2009-09-01 – 2020-11-06 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT05427305 · BioDlink Biopharm Co., Ltd.
2017-10-20 – 2020-03-24 · Efficacy
What this study did
NCT02272413 · Boehringer Ingelheim
2015-07-08 – 2018-11-16 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03169335 · Qilu Pharmaceutical Co., Ltd.
2017-03-28 – 2018-07-13 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT02879097 · Cipla BioTec Pvt. Ltd.
2016-12 – 2018-05 · Non-Small Cell Lung Carcinoma
What this study did
NCT01966003 · Amgen
2013-11-11 – 2015-07-23 · Non-small Cell Lung Cancer Metastatic
What this study did
Ovarian Cancer
NCT07286266 · GlaxoSmithKline
2026-06-18 – 2030-07-22 · Ovarian Neoplasms
What this study did
NCT04679064 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2020-12-01 – 2025-01-01 · Ovarian Cancer
What this study did
NCT03642132 · Pfizer
2018-07-19 – 2021-12-22 · Ovarian Cancer
What this study did
Recurrent Glioblastoma
NCT02017717 · Bristol-Myers Squibb
2014-02-07 – 2024-06-21 · Recurrent Glioblastoma
What this study did
Other / comorbidity
NCT03148418 · Hoffmann-La Roche
2017-09-20 – 2026-11-30 · Cancer
What this study did
NCT03220932 · Hospices Civils de Lyon
2019-11-30 – 2022-11-30 · Ovarian Epithelial Cancer
What this study did
NCT03462251 · iOMEDICO AG
2018-05-24 – 2022-11-30 · Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
What this study did
NCT03708536 · Fujian Cancer Hospital
2018-11 – 2022-11 · Colorectal Adenocarcinoma
What this study did
NCT00373256 · Pfizer
2006-11 – 2011-08 · Breast Neoplasms
What this study did
Phase 2/3 (6)
Cervical Cancer
NCT07472153 · N.N. Alexandrov National Cancer Centre
2025-07-01 – 2033-06-30 · Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer
What this study did
Hepatocellular Carcinoma
Metastatic Colorectal Cancer
NCT00384176 · AstraZeneca
2006-08-30 – 2015-08-19 · Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT02959749 · Qingdao Central Hospital
2015-08 – 2017-12-31 · Progression Free Survival
What this study did
Other / comorbidity
NCT02414165 · Tocagen Inc.
2015-11-30 – 2019-12-20 · Glioblastoma Multiforme, Anaplastic Astrocytoma
What this study did
NCT01523314 · King Saud University
2012-03 – 2013-02 · Diabetic Macular Edema
What this study did
Phase 2 (44)
Cervical Cancer
NCT04974944 · Sun Yat-Sen University Cancer Center
2021-07-30 – 2024-01-08 · Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
What this study did
Colorectal Cancer
NCT07895355 · RemeGen Co., Ltd.
2026-11 – 2030-01 · Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
What this study did
NCT00200200 · Memorial Sloan Kettering Cancer Center
2004-11-19 – 2025-03-13 · Hepatic Metastases, Colon Cancer, Rectal Cancer
What this study did
NCT05648006 · Binhui Biopharmaceutical Co., Ltd.
2023-10-17 – 2024-04-15 · Advanced Colorectal Carcinoma
What this study did
NCT03271255 · Shenzhen People's Hospital
2018-05-23 – 2022-12-31 · Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
What this study did
NCT02515734 · Japan Clinical Cancer Research Organization
2015-08 – 2020-06 · Colorectal Cancer
What this study did
Hepatocellular Carcinoma
NCT05760430 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-12-14 – 2024-12 · Hepatocellular Carcinoma
What this study did
NCT04393220 · Fuda Cancer Hospital, Guangzhou
2020-05-11 – 2021-08-31 · Progress Free Survival (PFS) and Overall Survival (OS)
What this study did
Metastatic Colorectal Cancer
NCT07359456 · UNICANCER
2026-08-31 – 2033-08 · Metastatic Colorectal Cancer
What this study did
NCT05007132 · Dominik Paul Modest
2021-12-17 – 2032-12 · Metastatic Colorectal Cancer
What this study did
NCT06039202 · Holy Stone Healthcare Co., Ltd
2027-12 – 2031-09 · Metastatic Colorectal Cancer
What this study did
NCT07381764 · Gruppo Oncologico Italia Meridionale
2026-03-20 – 2031-03-30 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT06856837 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-10-27 – 2029-12-31 · Metastatic Colorectal Cancer
What this study did
NCT07286695 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2029-12-31 · Metastatic Colorectal Cancer (CRC), Colorectal Cancer
What this study did
NCT06887218 · The Methodist Hospital Research Institute
2025-05-08 – 2029-12 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT07021950 · Sun Yat-sen University
2025-08-10 – 2028-12-31 · Colorectal Cancer, Ivonescimab
What this study did
NCT07150403 · Federation Francophone de Cancerologie Digestive
2025-12-31 – 2028-10-31 · Metastatic Colorectal Carcinoma (mCRC)
What this study did
NCT07051785 · Liu Huang
2025-07-07 – 2028-07-06 · Colorectal Cancer (CRC)
What this study did
NCT07261709 · Sun Yat-sen University
2025-12-01 – 2028-03-30 · Refractory Metastatic Colorectal Cancer
What this study did
NCT06493760 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2024-09-03 – 2027-06 · Metastatic Colorectal Cancer
What this study did
NCT05555901 · Fudan University
2023-06-18 – 2025-09 · Metastatic Colorectal Cancer
What this study did
NCT03186326 · Federation Francophone de Cancerologie Digestive
2018-04-24 – 2025-03-01 · Metastatic Colorectal Cancer, MSI
What this study did
NCT05068206 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021-10-08 – 2024-06 · Unresectable Metastatic Colorectal Cancer
What this study did
NCT04034459 · Ludwig-Maximilians - University of Munich
2016-11-25 – 2023-12-31 · Metastatic Colorectal Cancer
What this study did
NCT04733963 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-03-01 – 2023-02-01 · Colorectal Cancer
What this study did
NCT02141295 · Hoffmann-La Roche
2014-06-30 – 2017-02-01 · Colorectal Cancer
What this study did
NCT00819780 · Amgen
2009-04-24 – 2016-07-07 · Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
What this study did
NCT01478594 · AVEO Pharmaceuticals, Inc.
2011-12 – 2015-01 · Colorectal Cancer
What this study did
NCT00609622 · Pfizer
2008-04 – 2011-07 · Colorectal Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT07001618 · Gustave Roussy, Cancer Campus, Grand Paris
2025-11-17 – 2032-09 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT00600821 · Pfizer
2008-04 – 2012-10 · Non-Small-Cell Lung Carcinoma, Adenocarcinoma
What this study did
NCT00369070 · Amgen
2007-01-31 – 2011-08-03 · Advanced Non-squamous NSCLC
What this study did
Recurrent Glioblastoma
NCT07297212 · BioNTech SE
2026-01-15 – 2029-07 · Recurrent Glioblastoma
What this study did
Renal Cell Carcinoma
NCT00378703 · National Cancer Institute (NCI)
2007-09-14 – 2017-03-21 · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
What this study did
Other / comorbidity
NCT04832776 · Fudan University
2021-04-17 – 2025-12-31 · Liver Metastasis Colon Cancer
What this study did
NCT02299999 · UNICANCER
2014-04-07 – 2025-12 · Metastatic Breast Cancer
What this study did
NCT02364713 · Mayo Clinic
2015-03-13 – 2022-01-13 · Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT01471054 · Arman Mashayekhi
2014-04 – 2015-07 · Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
What this study did
NCT02060955 · CytoVac A/S
2014-02 – 2015-07 · Glioblastoma Multiforme
What this study did
NCT00356681 · Amgen
2006-12 – 2012-08 · Breast Neoplasms, Breast Tumors, Breast Cancer, Locally Recurrent and Metastatic Breast Cancer
What this study did
Phase 1/2 (8)
Colorectal Cancer
NCT07012954 · Sun Yat-sen University
2025-06-01 – 2030-12-31 · Colorectal Cancer Metastatic
What this study did
NCT04421820 · Bold Therapeutics, Inc.
2020-08-28 – 2027-12-31 · Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
What this study did
Hepatocellular Carcinoma
NCT06530251 · Akeso
2024-09-24 – 2028-09 · Hepatocellular Carcinoma
What this study did
Metastatic Colorectal Cancer
NCT06195670 · Zhejiang Cancer Hospital
2024-01 – 2027-01 · CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
What this study did
NCT01937715 · Pfizer
2014-02 – 2015-08 · Metastatic Colorectal Carcinoma
What this study did
NCT00460603 · Pfizer
2006-01 – 2012-11 · Colorectal Neoplasms
What this study did
Other / comorbidity
NCT06584071 · Biotheus Inc.
2024-12 – 2027-12 · HCC, Liver Cancer
What this study did
Phase 1 (15)
Metastatic Colorectal Cancer
NCT05110118 · Shandong Boan Biotechnology Co., Ltd
2020-08-04 – 2021-01-13 · Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
What this study did
Non-Small Cell Lung Cancer
NCT04175158 · Genor Biopharma Co., Ltd.
2017-04-24 – 2020-11 · Non-small Cell Lung Cancer
What this study did
NCT03030430 · Bio-Thera Solutions
2016-03-15 – 2017-06-28 · NSCLC
What this study did
Other / comorbidity
NCT06232902 · Qilu Pharmaceutical Co., Ltd.
2024-06-20 – 2024-11-18 · Tumor
What this study did
NCT05113511 · First Affiliated Hospital of Zhejiang University
2018-05-09 – 2021-07-26 · Healthy
What this study did
NCT04126044 · Pfizer
2021-01-22 – 2021-07-10 · Pharmacokinetics
What this study did
NCT04135898 · Shanghai Institute Of Biological Products
2019-10-23 – 2020-03-16 · Healthy Male
What this study did
NCT03576651 · JHL Biotech, Inc.
2018-03-24 – 2019-12-13 · Healthy Male Subjects
What this study did
NCT03882424 · Zhejiang Teruisi Pharmaceutical Inc.
2018-06-12 – 2018-10-25 · Healthy
What this study did
NCT03131700 · TRPHARM
2017-12 – 2018-01 · Healthy
What this study did
NCT03483649 · Shanghai Henlius Biotech
2017-04-21 – 2017-10-29 · Healthy Male Subjects
What this study did
NCT03115762 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
2017-06 – 2017-07 · Healthy
What this study did
NCT02747823 · Cipla BioTec Pvt. Ltd.
2016-06 – 2016-12 · Healthy
What this study did
NCT02453672 · Samsung Bioepis Co., Ltd.
2015-04 – 2015-09 · Healthy
What this study did
NCT01608087 · Boehringer Ingelheim
2012-05-01 – 2012-11-01 · Healthy
What this study did
Phase 4 (7)
Colorectal Cancer
NCT07094893 · Gruppo Oncologico del Nord-Ovest
2026-09-15 – 2030-03 · Colorectal Cancer
What this study did
Other / comorbidity
NCT07358520 · Fudan University
2026-01-28 – 2028-01-28 · Proteinuria
What this study did
NCT06850571 · Al-Mustansiriyah University
2025-02-20 – 2025-12-01 · Diabetic Maculopathy
What this study did
NCT03832179 · Bay Area Retina Associates
2018-11-15 – 2024-03-30 · Diabetic Macular Edema, Cataract
What this study did
NCT05514925 · Khairallah Moncef
2017-11-21 – 2022-12-31 · Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment
What this study did
NCT04619303 · Lions Eye Institute, Perth, Western Australia
2017-02-07 – 2020-02-14 · Diabetic Macular Edema, Diabetic Retinopathy
What this study did
NCT03148132 · Universidad Autonoma de San Luis Potosí
2017-05-23 – 2018-08-30 · Retinopathy of Prematurity Both Eyes, Retinal Disease, Premature Birth, Eye Diseases
What this study did
Early phase / not applicable (3)
Colorectal Cancer
NCT03743428 · Shenzhen People's Hospital
2020-10-22 – 2026-12-31 · Colorectal Neoplasms
What this study did
Other / comorbidity
NCT02698254 · M.D. Anderson Cancer Center
2016-07-20 – 2027-07-31 · Recurrent Brain Neoplasm
What this study did
NCT07338097 · CMH Multan Institute of Medical Sciences
2025-09-07 – 2026-02-07 · Diabetic Macular Edema (DME)
What this study did
Appears in other studies (87)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (33)
Cervical Cancer
NCT06459687 · Lee's Pharmaceutical Limited
2024-11-28 – 2028-09-01 · Cervical Cancer
What this study did
NCT04982237 · Akeso
2021-08-27 – 2025-12-30 · Cervical Cancer
What this study did
Colorectal Cancer
Hepatocellular Carcinoma
NCT07166406 · NRG Oncology
2026-02-26 – 2034-03-10 · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
What this study did
NCT05904886 · Hoffmann-La Roche
2023-09-14 – 2026-09-01 · Hepatocellular Carcinoma
What this study did
Metastatic Colorectal Cancer
NCT07025239 · Qilu Pharmaceutical Co., Ltd.
2025-07 – 2029-07 · Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03117049 · Ono Pharmaceutical Co., Ltd.
2017-06-13 – 2023-12-04 · Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT07791732 · Daiichi Sankyo
2027-03-31 – 2033-12-01 · Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
What this study did
NCT07851025 · AstraZeneca
2026-09-16 – 2033-08-29 · Epithelial Ovarian Cancer
What this study did
NCT07811271 · BeOne Medicines
2026-10 – 2033-03-31 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT07318558 · Merck Sharp & Dohme LLC
2026-02-16 – 2033-02-25 · Ovarian Neoplasms, Ovarian Cancer
What this study did
NCT06824467 · Merck Sharp & Dohme LLC
2025-04-09 – 2032-11-09 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT07694427 · GlaxoSmithKline
2026-10-02 – 2032-11-08 · Ovarian Neoplasms
What this study did
NCT07816666 · AstraZeneca
2026-09-24 – 2031-10-30 · Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
What this study did
NCT07213804 · Eli Lilly and Company
2025-10-22 – 2031-08 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
What this study did
NCT05116189 · Merck Sharp & Dohme LLC
2021-12-13 – 2027-07-16 · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
What this study did
NCT03737643 · AstraZeneca
2019-01-04 – 2026-12-23 · Advanced Ovarian Cancer
What this study did
NCT03353831 · AGO Research GmbH
2018-09-11 – 2025-03-11 · Recurrent Ovarian Carcinoma
What this study did
NCT02891824 · ARCAGY/ GINECO GROUP
2016-09-22 – 2024-02-22 · Ovarian Cancer
What this study did
NCT03038100 · Hoffmann-La Roche
2017-03-08 – 2022-08-12 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
What this study did
Recurrent Glioblastoma
NCT06496971 · NaviFUS Corporation
2024-11-08 – 2027-03-31 · Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma, Brain Tumor, Brain Tumor, Recurrent, Neoplasms, Neoplasms, Nerve Tissue
What this study did
NCT05118776 · Ascletis Pharmaceuticals Co., Ltd.
2022-01-21 – 2025-06 · Recurrent Glioblastoma
What this study did
NCT02761070 · Kyorin University
2016-07-11 – 2025-04-17 · Glioblastoma, Recurrence, Progression
What this study did
NCT03149003 · Sumitomo Pharma America, Inc.
2017-12-08 – 2021-08-30 · Glioblastoma
What this study did
NCT05718466 · Henry Ford Health System
2010-11 – 2016-12 · Recurrent or Progressive Glioblastoma
What this study did
Other / comorbidity
NCT01940887 · Ophthotech Corporation
2014-05 – 2017-09 · Age-Related Macular Degeneration
What this study did
Phase 2/3 (4)
Cervical Cancer
NCT06755515 · Shandong New Time Pharmaceutical Co., LTD
2024-09-26 – 2028-09 · Cervical Cancer
What this study did
Hepatocellular Carcinoma
NCT07293468 · Tuen Mun Hospital
2024-04-01 – 2034-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
Metastatic Colorectal Cancer
NCT04547166 · Shanghai Henlius Biotech
2021-03-10 – 2026-12-30 · Metastatic Colorectal Cancer
What this study did
Other / comorbidity
NCT02229175 · University of California, San Francisco
2021-01-01 – 2027-01-01 · Diabetic Macular Edema
What this study did
Phase 2 (38)
Colorectal Cancer
NCT07003022 · Fudan University
2025-06-01 – 2028-05-01 · Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
What this study did
NCT06590259 · Shanghai 6th People's Hospital
2024-03-12 – 2027-12 · Colorectal Cancer Liver Metastasis
What this study did
NCT03164655 · UNICANCER
2018-07-25 – 2021-11-15 · Colorectal Cancer Metastatic
What this study did
NCT00106054 · Pfizer
2006-01 – 2006-09 · Colorectal Neoplasms, Liver Neoplasms
What this study did
Hepatocellular Carcinoma
NCT06860490 · Fudan University
2025-03-18 – 2028-03-10 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05690048 · Michael Dill
2025-07-16 – 2028-03 · Immunotherapy, HCC - Hepatocellular Carcinoma
What this study did
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
Metastatic Colorectal Cancer
NCT05375708 · UMC Utrecht
2025-12-01 – 2034-06-01 · Metastatic Colorectal Cancer, Oligometastatic Disease
What this study did
NCT06411600 · Vall d'Hebron Institute of Oncology
2024-05-17 – 2029-05-01 · Metastatic Colorectal Cancer
What this study did
NCT05983367 · Inspirna, Inc.
2023-10-10 – 2025-03-31 · Colorectal Cancer, Metastatic Colon Cancer
What this study did
NCT02873195 · Academic and Community Cancer Research United
2017-07-07 – 2023-12-01 · Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT02305758 · AbbVie
2014-12-02 – 2017-09-22 · Untreated Metastatic Colorectal Cancer
What this study did
NCT01418222 · Genentech, Inc.
2011-09-14 – 2013-03-18 · Colorectal Cancer
What this study did
NCT00636610 · Genentech, Inc.
2008-05 – 2010-12 · Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT00480831 · Genentech, Inc.
2007-06 – 2010-08 · Non-Small Cell Lung Cancer
What this study did
NCT00434226 · Genentech, Inc.
2007-03-27 – 2008-04-29 · Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT05200260 · Shanghai Gynecologic Oncology Group
2022-07-13 – 2027-06 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
Recurrent Glioblastoma
NCT01730950 · Radiation Therapy Oncology Group
2012-12-20 – 2022-12-22 · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
What this study did
NCT01609790 · National Cancer Institute (NCI)
2012-06-04 – 2022-05-20 · Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
What this study did
Other / comorbidity
NCT06482801 · Second Affiliated Hospital of Guangzhou Medical University
2024-06-10 – 2035-12-30 · Liver Cancer, Antibody
What this study did
NCT06483347 · Second Affiliated Hospital of Guangzhou Medical University
2024-04-04 – 2033-12-30 · Lung Cancer, Inoperable Disease
What this study did
NCT07784413 · Zhejiang Cancer Hospital
2026-09-01 – 2029-07-30 · Gastric Cancer Peritoneal Metastasis (GCPM)
What this study did
NCT07083375 · Zhijie Wang
2025-08-01 – 2027-06-01 · Extensive Small Cell Lung Cancer
What this study did
NCT01903330 · Epitopoietic Research Corporation
2014-03 – 2026-06 · Glioblastoma, Gliosarcoma
What this study did
NCT05611645 · Huashan Hospital
2022-10-01 – 2025-12 · Glioma, Recurrent Glioma
What this study did
NCT04508452 · First Affiliated Hospital of Zhejiang University
2020-05-18 – 2023-06-01 · Unresectable Metastatic Colorectal Carcinoma
What this study did
NCT00892177 · Alliance for Clinical Trials in Oncology
2009-10 – 2019-07-01 · Glioblastoma Multiforme
What this study did
NCT01305213 · National Cancer Institute (NCI)
2011-03-21 – 2016-11-03 · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT02663141 · Tehran University of Medical Sciences
2015-06 – 2016-06 · Diabetic Macular Edema
What this study did
NCT00777673 · University of Tennessee Cancer Institute
2008-10 – 2013-10 · Breast Cancer
What this study did
NCT01641406 · Auxilio Mutuo Cancer Center
2011-03 – 2013-03 · Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma
What this study did
NCT00434356 · Genentech, Inc.
2007-03 – 2008-05 · Metastatic Breast Cancer
What this study did
NCT00536939 · Eli Lilly and Company
2007-11 – 2008-03 · Breast Cancer
What this study did
Phase 1/2 (7)
Metastatic Colorectal Cancer
NCT00625651 · Amgen
2007-10 – 2011-09 · Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
What this study did
Other / comorbidity
NCT07831187 · First Affiliated Hospital of Wenzhou Medical University
2026-10-01 – 2029-09-30 · Glioblastoma
What this study did
NCT01933815 · Cortice Biosciences, Inc.
2013-08 – 2025-05 · Glioblastoma Multiforme
What this study did
NCT01468831 · National Eye Institute (NEI)
2012-03-28 – 2021-03-18 · Retinal Vein Occlusion
What this study did
NCT02857920 · Fuda Cancer Hospital, Guangzhou
2016-08-01 – 2019-08-01 · Malignant Solid Tumour
What this study did
NCT01468844 · National Eye Institute (NEI)
2011-12-21 – 2015-05-13 · Retinal Vein Occlusion
What this study did
NCT00932438 · University of Louisville
2009-06 – 2012-12 · Colon Cancer With Metastases to the Liver
What this study did
Phase 4 (1)
Other / comorbidity
NCT02462304 · The University of Hong Kong
2015-06 – 2017-12 · Diabetic Macula Edema
What this study did
Early phase / not applicable (4)
Hepatocellular Carcinoma
NCT05984511 · Third Affiliated Hospital, Sun Yat-Sen University
2023-08-30 – 2029-08-01 · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
What this study did
NCT06265350 · Sun Yat-sen University
2024-02-02 – 2027-01-30 · Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab, Bevacizumab, Cryoablation
What this study did
Other / comorbidity
NCT01231633 · Long Island Vitreoretinal Consultants
2010-09 – 2014-09 · Macular Edema, Central Retinal Vein Occlusion
What this study did
NCT00709657 · Medical University of Vienna
2008-03 – 2011-11 · Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bevacizumab: this drugApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Aflibercept (Eylea)
Approved(overall)
Protein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
Brolucizumab-Dbll
Approved(overall)
Antibody fragmentVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
Ranibizumab (Lucentis)
Approved(overall)
Antibody fragmentVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
APG-2449Phase 3Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
BAT5906
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CKD-701 (Lucenbies)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
HD204Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03390686: SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
HLX04-O
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
IBI305Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890
Phase 3(overall)
Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab And TuvonralimabPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
NiraparibPhase 3Small moleculePARP1/2Partial signal
NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)
Phase 3(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Savolitinib (Orpathys)Phase 3Small moleculeMETPartial signal
NCT05261399: SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib.
NCT05015608: Median PFS (SACHI trial, ITT): 8.2 months savolitinib+osimertinib vs 4.5 months chemotherapy; in patients prior on 1st/2nd-gen EGFR-TKI: 9.8 vs 5.4 months; predefined significance thresholds met in both populations
Surabgene Lomparvovec
Phase 3(overall)
Gene therapy / editingVEGF-A
Weak signal(overall)
No reviewed efficacy summary in this indication
Tarcocimab Tedromer
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
MW02
Phase 2/3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 2Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)Phase 2Antibody–drug conjugateTissue Factor (TF)Weak signalFeatured results are dose-finding only in this race
TUB-040Phase 2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 1/2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 1/2PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 1/2Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 1Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)
Phase 1(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 153 furthest-along competitors are listed; 485 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(458 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bevacizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (48)
November 2026 (4)
Phase 2GlioblastomaActive not recruiting
Est. primary completion 2026-11 · NCT03743662 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT04958811 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CancerRecruiting
Est. primary completion 2026-11 · NCT05991102 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2026-11-30 · NCT06160206 · CT.gov ↗
What to watch
December 2026 (44)
Phase 2RhabdomyosarcomaActive not recruiting
Est. primary completion 2026-12 · NCT01871766 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03786692 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2026-12 · NCT05281471 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05654454 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT06107413 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06607458 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06844474 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07233850 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT07512674 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-01 · NCT06683703 · CT.gov ↗
What to watch
Phase 2Overall Response RateRecruiting
Est. primary completion 2026-12-01 · NCT07090525 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT07192185 · CT.gov ↗
What to watch
Phase 2HER2-low Breast CancerRecruiting
Est. primary completion 2026-12-06 · NCT07446452 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Solid TumorsActive not recruiting
Est. primary completion 2026-12-15 · NCT06571422 · CT.gov ↗
What to watch
Phase 2GliomaRecruiting
Est. primary completion 2026-12-15 · NCT06801730 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2026-12-24 · NCT05843188 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-24 · NCT06783647 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small-cell Lung Cancer, Liver MetastasesRecruiting
Est. primary completion 2026-12-28 · NCT05588388 · CT.gov ↗
What to watch
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05171660 · CT.gov ↗
What to watch
Phase 2HER-2 Negative Breast CancerRecruiting
Est. primary completion 2026-12-30 · NCT05398861 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT06031285 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06465563 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT06982924 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07007767 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2026-12-30 · NCT07340164 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02210117 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT03303495 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT03401294 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03937830 · CT.gov ↗
What to watch
Phase 1Solid Tumors or LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05460767 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05488522 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT05636111 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT05727163 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05844046 · CT.gov ↗
What to watch
Phase 1Colon Cancer, Metastatic Colon CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05848739 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT05867420 · CT.gov ↗
What to watch
Phase 1/2Glioma, Glioblastoma MultiformeActive not recruiting
Est. primary completion 2026-12-31 · NCT06011109 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06280495 · CT.gov ↗
What to watch
Early phase / not applicableOvarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT06292286 · CT.gov ↗
What to watch
Phase 2Malignant AscitesRecruiting
Est. primary completion 2026-12-31 · NCT06433869 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT06696768 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07007728 · CT.gov ↗
What to watch
Phase 2Advanced Breast CancerEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07359404 · CT.gov ↗
What to watch
2027 (164)
January 2027 (8)
Phase 1Hematological Malignancy, Solid TumorRecruiting
Est. primary completion 2027-01 · NCT05828459 · CT.gov ↗
What to watch
Phase 2TNBC, Brain MetastasisRecruiting
Est. primary completion 2027-01 · NCT07623577 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-01-01 · NCT06971406 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-01-01 · NCT07276100 · CT.gov ↗
What to watch
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-01-19 · NCT05584670 · CT.gov ↗
What to watch
Early phase / not applicableGlioblastoma, Radiotherapy, ChemotherapyRecruiting
Est. primary completion 2027-01-20 · NCT03144167 · CT.gov ↗
What to watch
Phase 2Unresectable Metastatic Rectal Cancer, CAPOX, Combination of RadioimmunotherapyNot yet recruiting
Est. primary completion 2027-01-30 · NCT07059949 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-31 · NCT05096715 · CT.gov ↗
What to watch
February 2027 (10)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-02 · NCT06835179 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-02 · NCT07229846 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-02-01 · NCT06801665 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2027-02-02 · NCT02884648 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian, Fallopian Tube, Primary Peritoneal CancerActive not recruiting
Est. primary completion 2027-02-02 · NCT05053750 · CT.gov ↗
What to watch
Phase 2Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)Active not recruiting
Est. primary completion 2027-02-10 · NCT06271837 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-02-15 · NCT05377034 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-02-20 · NCT01684397 · CT.gov ↗
What to watch
Phase 2Liver MetastasesRecruiting
Est. primary completion 2027-02-28 · NCT05062317 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch
March 2027 (10)
Phase 1/2Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma …Active not recruiting
Est. primary completion 2027-03 · NCT01837862 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerActive not recruiting
Est. primary completion 2027-03 · NCT05141721 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT05516628 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07246668 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-03-15 · NCT05231122 · CT.gov ↗
What to watch
Phase 4Carcinoma, Ovarian EpithelialActive not recruiting
Est. primary completion 2027-03-15 · NCT06121401 · CT.gov ↗
What to watch
Early phase / not applicableProliferative Diabetic Retinopathy - High RiskRecruiting
Est. primary completion 2027-03-20 · NCT06899529 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-25 · NCT04227028 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT06427941 · CT.gov ↗
What to watch
April 2027 (14)
Phase 3Ovarian CancerActive not recruiting
Est. primary completion 2027-04 · NCT05445778 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04 · NCT07560488 · CT.gov ↗
What to watch
Phase 3Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, AdultRecruiting
Est. primary completion 2027-04-01 · NCT05271240 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2027-04-01 · NCT05919264 · CT.gov ↗
What to watch
Phase 1Acute LeukemiaNot yet recruiting
Est. primary completion 2027-04-01 · NCT06876701 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04-01 · NCT06995105 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-04-16 · NCT06106308 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-04-25 · NCT06595108 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaEnrolling by invitation
Est. primary completion 2027-04-30 · NCT05185505 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-04-30 · NCT06397222 · CT.gov ↗
What to watch
Phase 2Hepato Cellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-04-30 · NCT06742424 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-30 · NCT06799065 · CT.gov ↗
What to watch
Phase 2Endometrial Adenocarcinoma, Endometrial CancerRecruiting
Est. primary completion 2027-04-30 · NCT06917092 · CT.gov ↗
What to watch
May 2027 (10)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05 · NCT03896074 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05 · NCT06986785 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-05 · NCT07014215 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2027-05 · NCT07054567 · CT.gov ↗
What to watch
Phase 1Colorectal CancerNot yet recruiting
Est. primary completion 2027-05-01 · NCT06882915 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-05-17 · NCT06420973 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-25 · NCT05440708 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT04721132 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-05-31 · NCT06004245 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-05-31 · NCT07559760 · CT.gov ↗
What to watch
June 2027 (19)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT04999761 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-06 · NCT06427239 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07244926 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2027-06 · NCT07653685 · CT.gov ↗
What to watch
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT02997228 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06557096 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2027-06-01 · NCT06576037 · CT.gov ↗
What to watch
Phase 3Ovarian Clear Cell CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT07002346 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerActive not recruiting
Est. primary completion 2027-06-16 · NCT05627635 · CT.gov ↗
What to watch
Phase 1/2Tumours, GynecologicalRecruiting
Est. primary completion 2027-06-21 · NCT06796907 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2027-06-30 · NCT05112965 · CT.gov ↗
What to watch
Phase 1/2Advanced/Metastatic Solid TumorsRecruiting
Est. primary completion 2027-06-30 · NCT05405595 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-06-30 · NCT05739981 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT06792695 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT06953843 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-06-30 · NCT07150247 · CT.gov ↗
What to watch
Phase 1/2Solid TumorNot yet recruiting
Est. primary completion 2027-06-30 · NCT07612137 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-06-30 · NCT07870772 · CT.gov ↗
What to watch
July 2027 (13)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-07 · NCT04803994 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07 · NCT05005403 · CT.gov ↗
What to watch
Early phase / not applicableLocally Advanced Rectal Cancer (LARC), 5-12cm to Anal VergeNot yet recruiting
Est. primary completion 2027-07-01 · NCT07769853 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
Phase 1/2Advanced Liver CancersActive not recruiting
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-07-30 · NCT06096779 · CT.gov ↗
What to watch
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-07-31 · NCT03181100 · CT.gov ↗
What to watch
Phase 2Respiratory Tract Diseases, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Squamous Cell …Active not recruiting
Est. primary completion 2027-07-31 · NCT05797246 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-07-31 · NCT05985798 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (GC)Not yet recruiting
Est. primary completion 2027-07-31 · NCT07045805 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-07-31 · NCT07106034 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-07-31 · NCT07138885 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-07-31 · NCT07714317 · CT.gov ↗
What to watch
August 2027 (11)
Phase 1Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)Active not recruiting
Est. primary completion 2027-08 · NCT01189643 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08 · NCT06695026 · CT.gov ↗
What to watch
Phase 1/2Cervical CancerRecruiting
Est. primary completion 2027-08 · NCT07080216 · CT.gov ↗
What to watch
Phase 2Peritoneal Malignant MesotheliomaRecruiting
Est. primary completion 2027-08-01 · NCT05001880 · CT.gov ↗
What to watch
Phase 4Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07059494 · CT.gov ↗
What to watch
Phase 2Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102, BevacizumabRecruiting
Est. primary completion 2027-08-01 · NCT07085169 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07733050 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-08-30 · NCT07446322 · CT.gov ↗
What to watch
Phase 3Venous ThrombosisActive not recruiting
Est. primary completion 2027-08-31 · NCT04649489 · CT.gov ↗
What to watch
Phase 2Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell CarcinomaActive not recruiting
Est. primary completion 2027-08-31 · NCT06023862 · CT.gov ↗
What to watch
Phase 2mCRCNot yet recruiting
Est. primary completion 2027-08-31 · NCT07116577 · CT.gov ↗
What to watch
September 2027 (18)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-09 · NCT06084481 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT06679985 · CT.gov ↗
What to watch
Phase 2Adhesive CapsulitisRecruiting
Est. primary completion 2027-09 · NCT06976671 · CT.gov ↗
What to watch
Phase 2Breast Cancer With Brain Metastasis, HER2-low Expressing Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07150208 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT05976568 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-09-01 · NCT06788171 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07123441 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07774247 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07819604 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-09-10 · NCT05192798 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-23 · NCT04837716 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-09-27 · NCT01061515 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2027-09-28 · NCT06233942 · CT.gov ↗
What to watch
Phase 2Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-09-30 · NCT03074513 · CT.gov ↗
What to watch
Early phase / not applicableRecurrent GlioblastomaRecruiting
Est. primary completion 2027-09-30 · NCT05284643 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-09-30 · NCT06083844 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-09-30 · NCT07474727 · CT.gov ↗
What to watch
October 2027 (9)
Phase 2/3Rectal CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07134218 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07134413 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10 · NCT07478302 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07497074 · CT.gov ↗
What to watch
Phase 3Diabetic Macular Edema (DME)Enrolling by invitation
Est. primary completion 2027-10 · NCT07897630 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-10-20 · NCT07407465 · CT.gov ↗
What to watch
Phase 2Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part SarcomaActive not recruiting
Est. primary completion 2027-10-31 · NCT03141684 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT06547385 · CT.gov ↗
What to watch
November 2027 (5)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-11 · NCT05029882 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-11-10 · NCT07239245 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
Phase 1/2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-11-15 · NCT07933419 · CT.gov ↗
What to watch
Phase 1Solid Tumor, AdultRecruiting
Est. primary completion 2027-11-30 · NCT06265688 · CT.gov ↗
What to watch
December 2027 (37)
Phase 2DIPGRecruiting
Est. primary completion 2027-12 · NCT04250064 · CT.gov ↗
What to watch
Phase 3Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration …Active not recruiting
Est. primary completion 2027-12 · NCT05112861 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2027-12 · NCT05482893 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT06303505 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12 · NCT06906341 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07179900 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT07522411 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT05733598 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2027-12-01 · NCT07347951 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2027-12-01 · NCT07670026 · CT.gov ↗
What to watch
Phase 1GBMNot yet recruiting
Est. primary completion 2027-12-01 · NCT07909811 · CT.gov ↗
What to watch
Phase 2Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma …Active not recruiting
Est. primary completion 2027-12-15 · NCT03587311 · CT.gov ↗
What to watch
Phase 2/3Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2027-12-15 · NCT05063552 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-15 · NCT06893887 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-12-25 · NCT07042802 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumourRecruiting
Est. primary completion 2027-12-26 · NCT07111546 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT06663306 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07119931 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07197008 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12-30 · NCT07311577 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07314619 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT07327788 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-12-30 · NCT07380633 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT07398599 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT07416058 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-30 · NCT07503756 · CT.gov ↗
What to watch
Early phase / not applicableESCCRecruiting
Est. primary completion 2027-12-30 · NCT07627347 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04449874 · CT.gov ↗
What to watch
Phase 2Pan-tumorRecruiting
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT04981509 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06478693 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06540261 · CT.gov ↗
What to watch
Phase 2Locally Advanced Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06752382 · CT.gov ↗
What to watch
Phase 2Advanced Gynecological MalignanciesRecruiting
Est. primary completion 2027-12-31 · NCT07448922 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07490262 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07562490 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07750041 · CT.gov ↗
What to watch
2028 (133)
January 2028 (11)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-01 · NCT06563986 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-01 · NCT07024784 · CT.gov ↗
What to watch
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Dyspnea Caused by 2019-nCoVNot yet recruiting
Est. primary completion 2028-01-01 · NCT07089719 · CT.gov ↗
What to watch
Phase 2/3Cerebral AV MalformationRecruiting
Est. primary completion 2028-01-15 · NCT06264531 · CT.gov ↗
What to watch
Phase 1/2Melanoma Brain MetastasesRecruiting
Est. primary completion 2028-01-30 · NCT06163820 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-01-30 · NCT06294548 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-01-30 · NCT07128251 · CT.gov ↗
What to watch
Phase 2mCRC, HER2, Targeted Therapy, Antibody-drug ConjugatesNot yet recruiting
Est. primary completion 2028-01-30 · NCT07355764 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-31 · NCT01217931 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-01-31 · NCT07941310 · CT.gov ↗
What to watch
February 2028 (11)
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-02 · NCT04727307 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-02 · NCT07178717 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2028-02 · NCT07470853 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-02-01 · NCT06728865 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-02-01 · NCT07337551 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-02-14 · NCT07277270 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-02-15 · NCT06948448 · CT.gov ↗
What to watch
Phase 1/2Advanced Cholangiocarcinoma, FGFR2 FusionRecruiting
Est. primary completion 2028-02-22 · NCT06439485 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-02-25 · NCT06663319 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-02-28 · NCT07070713 · CT.gov ↗
What to watch
March 2028 (10)
Phase 2Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-typeRecruiting
Est. primary completion 2028-03 · NCT05742425 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-03 · NCT06820463 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-03 · NCT07066657 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-03-04 · NCT06642844 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-03-27 · NCT05528952 · CT.gov ↗
What to watch
Phase 2Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Recruiting
Est. primary completion 2028-03-27 · NCT07518602 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2028-03-30 · NCT05039801 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2028-03-30 · NCT07263438 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07776171 · CT.gov ↗
What to watch
Early phase / not applicableBiliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-03-31 · NCT07466238 · CT.gov ↗
What to watch
April 2028 (14)
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2028-04 · NCT07244705 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-04 · NCT07479485 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07551778 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-04-01 · NCT06733038 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-04-01 · NCT07515625 · CT.gov ↗
What to watch
Early phase / not applicableCorneal NeovascularisationRecruiting
Est. primary completion 2028-04-01 · NCT07642960 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-04-15 · NCT07193862 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaActive not recruiting
Est. primary completion 2028-04-28 · NCT07009470 · CT.gov ↗
What to watch
Phase 1Advanced CancerActive not recruiting
Est. primary completion 2028-04-30 · NCT01187199 · CT.gov ↗
What to watch
Phase 2Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma …Recruiting
Est. primary completion 2028-04-30 · NCT04919629 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04-30 · NCT06839105 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerEnrolling by invitation
Est. primary completion 2028-04-30 · NCT06936527 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-04-30 · NCT07714668 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07915921 · CT.gov ↗
What to watch
May 2028 (4)
Early phase / not applicableColorectal CancerActive not recruiting
Est. primary completion 2028-05 · NCT01792934 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Solid TumorsRecruiting
Est. primary completion 2028-05 · NCT07824934 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2028-05-31 · NCT05101070 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
June 2028 (11)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07535632 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-06-18 · NCT06971744 · CT.gov ↗
What to watch
Phase 2BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain …Active not recruiting
Est. primary completion 2028-06-30 · NCT03175432 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2028-06-30 · NCT04516447 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT06737913 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-06-30 · NCT06787612 · CT.gov ↗
What to watch
Phase 1/2Malignant AscitesRecruiting
Est. primary completion 2028-06-30 · NCT07397819 · CT.gov ↗
What to watch
Phase 2TNBC, Triple Negative Breast Cancer, Brain MetastasasesRecruiting
Est. primary completion 2028-06-30 · NCT07638852 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2028-06-30 · NCT07774611 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07841574 · CT.gov ↗
What to watch
Phase 2Peritoneal Mesothelioma, First-line TherapyNot yet recruiting
Est. primary completion 2028-06-30 · NCT07893340 · CT.gov ↗
What to watch
July 2028 (12)
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2028-07 · NCT06268015 · CT.gov ↗
What to watch
Phase 2Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress SyndromeRecruiting
Est. primary completion 2028-07 · NCT06701656 · CT.gov ↗
What to watch
Phase 2Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress SyndromeRecruiting
Est. primary completion 2028-07 · NCT06703073 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2028-07 · NCT06859762 · CT.gov ↗
What to watch
Phase 3Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity, Radiation Effect, Radiation Injury …Recruiting
Est. primary completion 2028-07 · NCT06888817 · CT.gov ↗
What to watch
Phase 3Advanced Endometrial Carcinoma, Recurrent Endometrial CarcinomaRecruiting
Est. primary completion 2028-07-01 · NCT07198074 · CT.gov ↗
What to watch
Phase 4Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-07-01 · NCT07619235 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-07-25 · NCT07062055 · CT.gov ↗
What to watch
Phase 1Colorectal CancerNot yet recruiting
Est. primary completion 2028-07-31 · NCT07656038 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-07-31 · NCT07722754 · CT.gov ↗
What to watch
August 2028 (9)
Phase 3Radionecrosis of Brain, Brain MetastasesRecruiting
Est. primary completion 2028-08 · NCT06471465 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07681297 · CT.gov ↗
What to watch
Phase 2Ovary CancerRecruiting
Est. primary completion 2028-08-01 · NCT06540729 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-04 · NCT05797168 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-08-15 · NCT07420439 · CT.gov ↗
What to watch
Phase 2Lung Neoplasms, Pulmonary Neoplasms, Lymph Node Involvement, Pulmonary NoduleNot yet recruiting
Est. primary completion 2028-08-17 · NCT06809946 · CT.gov ↗
What to watch
Early phase / not applicableRecurrent GlioblastomaRecruiting
Est. primary completion 2028-08-31 · NCT07074756 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-08-31 · NCT07134101 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07543510 · CT.gov ↗
What to watch
September 2028 (12)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-09 · NCT02885753 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-09 · NCT05854498 · CT.gov ↗
What to watch
Phase 1/2Advan'ce'd, AdvancedNot yet recruiting
Est. primary completion 2028-09 · NCT07361991 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2028-09 · NCT07637851 · CT.gov ↗
What to watch
Early phase / not applicableMalignant Pleural Effusions (Mpe)Not yet recruiting
Est. primary completion 2028-09-01 · NCT07670338 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2028-09-25 · NCT07351487 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06133062 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2028-09-30 · NCT06445062 · CT.gov ↗
What to watch
Phase 2ORR,OS,PFSNot yet recruiting
Est. primary completion 2028-09-30 · NCT07328802 · CT.gov ↗
What to watch
Phase 3Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-09-30 · NCT07669610 · CT.gov ↗
What to watch
Phase 2Phase 2 StudyNot yet recruiting
Est. primary completion 2028-09-30 · NCT07817888 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07843303 · CT.gov ↗
What to watch
October 2028 (7)
Phase 1/2Glioblastoma Multiforme, Anaplastic AstrocytomaRecruiting
Est. primary completion 2028-10 · NCT01269853 · CT.gov ↗
What to watch
Phase 1Ovarian CancerNot yet recruiting
Est. primary completion 2028-10 · NCT07772882 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-08 · NCT07288034 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsNot yet recruiting
Est. primary completion 2028-10-15 · NCT07833735 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-10-27 · NCT06789757 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-10-31 · NCT07722494 · CT.gov ↗
What to watch
November 2028 (3)
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-11 · NCT06625775 · CT.gov ↗
What to watch
Phase 1Brain Arteriovenous MalformationsNot yet recruiting
Est. primary completion 2028-11-01 · NCT07075757 · CT.gov ↗
What to watch
Phase 2Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical SiteNot yet recruiting
Est. primary completion 2028-11-30 · NCT07547592 · CT.gov ↗
What to watch
December 2028 (29)
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2028-12 · NCT03351296 · CT.gov ↗
What to watch
Phase 1Ewing Sarcoma, Colorectal AdenocarcinomaRecruiting
Est. primary completion 2028-12 · NCT03715933 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2028-12 · NCT04121455 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-12 · NCT05009082 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT05579366 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT06680258 · CT.gov ↗
What to watch
Early phase / not applicableCervical CancerNot yet recruiting
Est. primary completion 2028-12 · NCT06878196 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorsRecruiting
Est. primary completion 2028-12 · NCT06895928 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07071844 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2028-12 · NCT07278336 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-12 · NCT07527858 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07557251 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07737600 · CT.gov ↗
What to watch
Early phase / not applicableRecurrent GlioblastomaNot yet recruiting
Est. primary completion 2028-12-01 · NCT07274787 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-01 · NCT07331883 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-05 · NCT07317414 · CT.gov ↗
What to watch
Phase 2Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT06492408 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT07058428 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07729605 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07895992 · CT.gov ↗
What to watch
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04017455 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaEnrolling by invitation
Est. primary completion 2028-12-31 · NCT05441475 · CT.gov ↗
What to watch
Phase 4PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, BevacizumabNot yet recruiting
Est. primary completion 2028-12-31 · NCT07004335 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07035808 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07281664 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07391566 · CT.gov ↗
What to watch
Phase 2Glioma, AdultRecruiting
Est. primary completion 2028-12-31 · NCT07678684 · CT.gov ↗
What to watch
2029 (60)
January 2029 (4)
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01 · NCT05363722 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2029-01 · NCT07059845 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01 · NCT07324824 · CT.gov ↗
What to watch
Phase 1Chronic Subdural HematomaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07729098 · CT.gov ↗
What to watch
February 2029 (5)
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07900165 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2029-02-01 · NCT04712643 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-02-01 · NCT07395063 · CT.gov ↗
What to watch
Phase 1Solid Tumors, Advanced Solid TumorsNot yet recruiting
Est. primary completion 2029-02-27 · NCT07904845 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-02-28 · NCT07472647 · CT.gov ↗
What to watch
March 2029 (5)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-03-06 · NCT07661173 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2029-03-27 · NCT06843447 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-30 · NCT06339424 · CT.gov ↗
What to watch
Phase 2HCCRecruiting
Est. primary completion 2029-03-31 · NCT06823375 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-03-31 · NCT07010497 · CT.gov ↗
What to watch
April 2029 (6)
Phase 2MesotheliomaNot yet recruiting
Est. primary completion 2029-04 · NCT07514793 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07663513 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07797244 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2029-04-12 · NCT07504588 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2029-04-14 · NCT07318805 · CT.gov ↗
What to watch
Phase 3Rectal Adenocarcinoma, High-Risk Cancer, MSSRecruiting
Est. primary completion 2029-04-30 · NCT07549399 · CT.gov ↗
What to watch
May 2029 (3)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2029-05 · NCT07525206 · CT.gov ↗
What to watch
Phase 1Solid Tumors, Advanced Solid Tumors, Metastatic Solid TumorsRecruiting
Est. primary completion 2029-05-03 · NCT05836324 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2029-05-27 · NCT07863869 · CT.gov ↗
What to watch
June 2029 (7)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT06400472 · CT.gov ↗
What to watch
Phase 1Recurrent GlioblastomaRecruiting
Est. primary completion 2029-06-11 · NCT07541781 · CT.gov ↗
What to watch
Phase 2Short-course Radiotherapy Plus Chemotherapy …Recruiting
Est. primary completion 2029-06-24 · NCT07674732 · CT.gov ↗
What to watch
Phase 3Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma …Recruiting
Est. primary completion 2029-06-30 · NCT04181060 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT06605664 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2029-06-30 · NCT06953323 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-06-30 · NCT07728019 · CT.gov ↗
What to watch
July 2029 (4)
Phase 3Non-Resectable Pancreas CarcinomaRecruiting
Est. primary completion 2029-07-01 · NCT07235930 · CT.gov ↗
What to watch
Phase 2Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases, Tracheal Diseases …Not yet recruiting
Est. primary completion 2029-07-01 · NCT07756840 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-07-01 · NCT07870733 · CT.gov ↗
What to watch
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-08-31 · NCT07543783 · CT.gov ↗
What to watch
September 2029 (7)
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2029-09 · NCT04188145 · CT.gov ↗
What to watch
Phase 2Recurrent Triple-Negative Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06976944 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2029-09 · NCT07676162 · CT.gov ↗
What to watch
Phase 2Bevacizimab, HHTRecruiting
Est. primary completion 2029-09-01 · NCT07828015 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-12 · NCT06131840 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-15 · NCT07481786 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07761286 · CT.gov ↗
What to watch
October 2029 (5)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2029-10 · NCT04587128 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-10 · NCT07847671 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic Brainstem Glioma …Recruiting
Est. primary completion 2029-10-01 · NCT05956821 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2029-10-01 · NCT07835737 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2029-10-16 · NCT07549412 · CT.gov ↗
What to watch
November 2029 (2)
Phase 2/3Colorectal CancerActive not recruiting
Est. primary completion 2029-11 · NCT05462613 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-11-01 · NCT07621497 · CT.gov ↗
What to watch
December 2029 (10)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-12 · NCT07564141 · CT.gov ↗
What to watch
Phase 2Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, EpendymomaRecruiting
Est. primary completion 2029-12-01 · NCT04374305 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07926477 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-30 · NCT07182708 · CT.gov ↗
What to watch
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2029-12-30 · NCT07821606 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-31 · NCT03872661 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaActive not recruiting
Est. primary completion 2029-12-31 · NCT06061809 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT07283367 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07370818 · CT.gov ↗
What to watch
Phase 2Rectal Neoplasms MalignantNot yet recruiting
Est. primary completion 2029-12-31 · NCT07383285 · CT.gov ↗
What to watch
2030 (30)
January 2030 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-01-01 · NCT06254248 · CT.gov ↗
What to watch
February 2030 (3)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2030-02 · NCT06890338 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerRecruiting
Est. primary completion 2030-02-02 · NCT07221357 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2030-02-28 · NCT07779538 · CT.gov ↗
What to watch
March 2030 (4)
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-03-01 · NCT07392866 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Rectal CancerRecruiting
Est. primary completion 2030-03-09 · NCT07183865 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Rectal CancerRecruiting
Est. primary completion 2030-03-10 · NCT06928584 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
April 2030 (3)
Phase 2Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor RecurrentRecruiting
Est. primary completion 2030-04 · NCT01356290 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-04-01 · NCT05797467 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
May 2030 (6)
Phase 4Cervical CancerRecruiting
Est. primary completion 2030-05 · NCT07645625 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2030-05-01 · NCT06954584 · CT.gov ↗
What to watch
Early phase / not applicableLocally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2030-05-15 · NCT07854964 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2030-05-21 · NCT07684612 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2030-05-27 · NCT06469281 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-05-30 · NCT07594340 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990516 · CT.gov ↗
What to watch
August 2030 (4)
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2030-08 · NCT07805551 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-08 · NCT07882056 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-08-31 · NCT03942328 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2030-08-31 · NCT04929223 · CT.gov ↗
What to watch
September 2030 (2)
Phase 1/2Metastatic Colorectal CarcinomaRecruiting
Est. primary completion 2030-09-04 · NCT07791758 · CT.gov ↗
What to watch
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
December 2030 (6)
Phase 1/2Renal Cell CarcinomaRecruiting
Est. primary completion 2030-12 · NCT07239596 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2030-12-27 · NCT07500298 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-12-31 · NCT06791512 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerRecruiting
Est. primary completion 2030-12-31 · NCT06958419 · CT.gov ↗
What to watch
Phase 2Colorectal Liver Metastasis (CRLM)Recruiting
Est. primary completion 2030-12-31 · NCT06988852 · CT.gov ↗
What to watch
Phase 1/2Relapsed NeuroblastomaRecruiting
Est. primary completion 2030-12-31 · NCT07334301 · CT.gov ↗
What to watch
2031 (15)
January 2031 (1)
Phase 1/2Cervical CancerRecruiting
Est. primary completion 2031-01-31 · NCT06543576 · CT.gov ↗
What to watch
February 2031 (3)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2031-02-28 · NCT07271355 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerNot yet recruiting
Est. primary completion 2031-02-28 · NCT07585279 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2031-02-28 · NCT07647653 · CT.gov ↗
What to watch
March 2031 (1)
Phase 1/2Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma RecurrentRecruiting
Est. primary completion 2031-03-31 · NCT07346157 · CT.gov ↗
What to watch
June 2031 (2)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-06 · NCT06725121 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-06 · NCT07018947 · CT.gov ↗
What to watch
August 2031 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2031-08-31 · NCT07743164 · CT.gov ↗
What to watch
September 2031 (3)
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2031-09 · NCT07691762 · CT.gov ↗
What to watch
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-09 · NCT07813572 · CT.gov ↗
What to watch
Phase 1Neuroblastoma (NBL), Ewing Sarcoma, OsteosarcomaNot yet recruiting
Est. primary completion 2031-09-30 · NCT07897968 · CT.gov ↗
What to watch
October 2031 (2)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2031-10 · NCT07071714 · CT.gov ↗
What to watch
Phase 3Cervical CancerRecruiting
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
December 2031 (2)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2031-12-01 · NCT07720180 · CT.gov ↗
What to watch
Phase 2pMMR/MSS Locally Advanced Rectal CancerRecruiting
Est. primary completion 2031-12-31 · NCT07005570 · CT.gov ↗
What to watch
2032 (3)
March 2032 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2032-03-19 · NCT07776691 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2032-05-01 · NCT07797283 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2032-06 · NCT05468359 · CT.gov ↗
What to watch
2033 (2)
March 2033 (1)
Phase 3CancerRecruiting
Est. primary completion 2033-03-01 · NCT05862285 · CT.gov ↗
What to watch
June 2033 (1)
Phase 2/3Ovarian CancerRecruiting
Est. primary completion 2033-06-30 · NCT07472140 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2034-12-31 · NCT06580314 · CT.gov ↗
What to watch
2040 (1)
July 2040 (1)
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2040-07-01 · NCT05620771 · CT.gov ↗
What to watch
2043 (1)
July 2043 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2043-07 · NCT02487992 · CT.gov ↗
What to watch

See the full readout calendar ↗